首页> 外文期刊>In vivo. >Rethinking the Issue of Power Morcellation of Uterine Fibroids: Is Morcellation the Real Problem or Is this Another Symptom of Disparity in Healthcare Provision?
【24h】

Rethinking the Issue of Power Morcellation of Uterine Fibroids: Is Morcellation the Real Problem or Is this Another Symptom of Disparity in Healthcare Provision?

机译:重新思考子宫肌瘤的功率粉碎问题:粉碎是真正的问题,还是这是医疗保健服务差距的另一种症状?

获取原文
       

摘要

Power morcellation remains one of the most significant developments in minimal access surgery over the past decade, allowing many more patients to benefit from the least invasive surgical route. However, its use is not without controversy, particularly with regards to the risks of an undiagnosed leiomyosarcoma. Increased media and, in particular, on-going social media coverage since events in 2014 have only served to intensify the debate, culminating in the Food and Drug Administration essentially banning its use in the USA. Practice however continues to vary and this technique remains widely used in Europe and in particular the UK. The aim of this article was to review the development of power morcellation in gynaecology and the underlying risks, including that of undiagnosed leiomyosarcoma, as well as appraise the evolving literature on patient awareness and informed consent and the wider implications of morcellation restriction.
机译:在过去的十年中,动力粉碎技术仍是微创手术中最重要的发展之一,它使更多的患者受益于微创手术途径。但是,它的使用并非没有争议,特别是在未诊断的平滑肌肉瘤的风险方面。自2014年事件以来,媒体的增加,尤其是持续不断的社交媒体报道只是加剧了辩论,最终导致美国食品药品管理局(FDA)实质上禁止在美国使用该媒体。然而,实践不断变化,并且该技术在欧洲特别是英国仍然广泛使用。本文的目的是回顾妇科动力粉碎的发展和潜在风险,包括未诊断的平滑肌肉瘤的风险,以及评估有关患者意识和知情同意以及粉碎限制的广泛含义的文献。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号